PROTEOMIC SCREENING IDENTIFIES MEGAKARYOCYTE DERIVED PF4/CXCL4 AS A CRITICAL DRIVER OF MYELOFIBROSIS

EHA Library, Alessandro Malara, 385452

A PHASE 1 STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF BCL-2 INHIBITOR BGB-11417 IN ADULT PATIENTS WITH MATURE B-CELL MALIGNANCIES

EHA Library, Caixia Li, 386455

LONG-TERM OUTCOMES WITH CONTINUOUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: ANALYSIS OF TIME TO PROGRESSION

EHA Library, Thomas Kipps, 386456

UPDATED ANALYSIS OF BELLWAVE-001: A PHASE 1/2 OPEN-LABEL DOSE-EXPANSION STUDY OF THE EFFICACY AND SAFETY OF NEMTABRUTINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES

EHA Library, Farrukh Awan, 386457

THE CLL TREATMENT INFECTION MODEL – CLINICAL PROSPECTIVE VALIDATION AS PART OF THE PREVENT-ACALL TRIAL

EHA Library, Carsten Niemann, 386458

SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL

EHA Library, Florian Simon, 386459

CHARACTERIZATION OF ZANUBRUTINIB SAFETY/TOLERABILITY PROFILE AND COMPARISON WITH IBRUTINIB PROFILE IN PATIENTS WITH B-CELL MALIGNANCIES: POST HOC ANALYSIS OF A LARGE CLINICAL TRIAL SAFETY DATABASE

EHA Library, Jennifer R. Brown, 386460

COMPARISON OF TREATMENT-EMERGENT ADVERSE EVENTS OF ACALABRUTINIB AND ZANUBRUTINIB IN CLINICAL TRIALS IN B-CELL MALIGNANCIES: A SYSTEMATIC REVIEW AND META-ANALYSIS

EHA Library, Steven Hwang, 386461

UPDATED SAFETY AND EFFICACY RESULTS OF ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES WHO ARE INTOLERANT OF IBRUTINIB AND/OR ACALABRUTINIB

EHA Library, Mazyar Shadman, 386462

EARLY-STAGE MEASURABLE RESIDUAL DISEASE DYNAMICS AND IGHV REPERTOIRE RECONSTITUTION DURING VENETOCLAX AND OBINUTUZUMAB TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Paul Hengeveld, 386463

AN UPDATE OF SAFETY AND EFFICACY RESULTS FROM PHASE 1 STUDY OF LP-108, A NOVEL AND SELECTIVE BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS

EHA Library, Wei Xu, 386464

A FIRST-IN-HUMAN PHASE 1 STUDY OF ORAL LOXO-338, A SELECTIVE BCL2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES

EHA Library, Michal Kwiatek, 386465

TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINUTUZUMAB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL

EHA Library, Jan Burger, 386466

DECISION SUPPORT IN THE CLINICAL ROUTINE FOR RAPID AND RELIABLE DIAGNOSTIC WORKFLOWS WITH THE HEMA.TO PLATFORM

EHA Library, Karsten Miermans, 386467

ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY

EHA Library, Talha Munir, 386468

ZANUBRUTINIB VS IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA (R/R CLL/SLL): IMPACT ON HEALTH-RELATED QUALITY OF LIFE (HRQOL)

EHA Library, Barbara Eichhorst, 386469

REAL-WORLD DURATION OF VENETOCLAX TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA

EHA Library, Anna Teschemaker, 386470

A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS ZANUBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Alan Skarbnik, 386471

CUMULATIVE REVIEW OF HEART FAILURE WITH ACALABRUTINIB IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA USING DATA FROM CLINICAL TRIALS AND POST-MARKETING EXPERIENCE

EHA Library, Paolo Ghia, 386472

IBRUTINIB FOR TREATMENT OF RELAPSED-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: A MATCHING-ADJUSTED INDIRECT COMPARISON OF 3 RANDOMIZED PHASE 3 TRIALS

EHA Library, Paolo Ghia, 386474

VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT

EHA Library, Lydia Scarfò, 386475

RACIAL DISPARITIES IN REAL-WORLD TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH CLL

EHA Library, Joanna M. Rhodes, 386476

REAL-WORLD TREATMENT AND OUTCOMES OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING FIRST-LINE (1L) THERAPY IN THE NOVEL AGENT ERA: AN INTERNATIONAL STUDY

EHA Library, Frederick Lansigan, 386477

SAFETY AND EFFECTIVENESS IN NAIVE CLL PATIENTS TREATED WITH VEN AND OBI UNDER REAL-WORLD CONDITIONS - COMPARISON OF PATIENTS IN LINE OR OUT OF SCOPE WITH CLL14 TRIAL.

EHA Library, Holger Hebart, 386478

EFFECTIVENESS OF VENETOCLAX ACCORDING TO THE CHARACTERISTICS OF PATIENTS WITH CLL IN MONOTHERAPY AND COMBINATION WITH RITUXIMAB. INTERIM ANALYSIS OF REAL-LIFE DATA FROM VERONE STUDY

EHA Library, Loïc Ysebaert, 386479

REAL-WORLD EFFECTIVENESS OF VENETOCLAX-BASED REGIMENS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN ISRAEL: UPDATE FROM THE MULTICENTER PROSPECTIVE REVEAL STUDY

EHA Library, Yair Herishanu, 386480

IMPROVED SURVIVAL OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA BETWEEN 1998-2022, INCLUDING THE ERA OF TARGET THERAPIES WITH BCL2 AND BTK INHIBITORS.

EHA Library, Tamar Tadmor, 386481

CML LONG-TERM LEUKEMIC STEM CELL PERSISTENCE IS INFLUENCED BY MYELOFIBROSIS AT DIAGNOSIS

EHA Library, Henrike Jacobi, 386482

ALLELIC POLYMORPHISMS OF KIRS AND HLAS PREDICT FAVORABLE ACHIEVEMENT OF TREATMENT-FREE REMISSION IN CML: RESULTS FROM THE POKSTIC TRIAL, MULTICENTER RETROSPECTIVE OBSERVATIONAL STUDY

EHA Library, Hiroshi Ureshino, 386483

LIMITATIONS OF USING CD26+ LEUKEMIA STEM CELL QUANTITATION IN CML PATIENTS TO ASSESS RESIDUAL LEUKEMIA CLONE

EHA Library, Nikolay Kapranov, 386484

NOVEL THIAZOLIDINEDIONE WITH HDAC INHIBITING PROPERTIES OPTIMIZED FOR CHRONIC MYELOID LEUKEMIA TREATMENT

EHA Library, Anna Rams, 386485

PATHOGENESIS OF TYROSINE KINASE INHIBITOR–ASSOCIATED VASCULAR TOXICITY IN CHRONIC MYELOID LEUKEMIA

EHA Library, Ayala Gover Proaktor, 386486

DEVELOPMENT OF THE HIGHLY ACCURATE AND SENSITIVE METHOD USING THE CHIP-BASED DIGITAL PCR (LOAA) FOR THE DETECTION OF BCR::ABL1 TRANSCRIPTS DURING WHOLE PERIOD OF CHRONIC MYELOID LEUKEMIA TREATMENT

EHA Library, Hyun-Woo Song, 386487

BUPARLISIB A PROMISING THERAPEUTIC APPROACH IN CHRONIC MYELOID LEUKEMIA RESISTANT TO IMATINIB

EHA Library, Ana Bela Sarmento-Ribeiro, 386488

NEXT-GENERATION SEQUENCING (NGS) FOR DETECTING BCR::ABL-INDEPENDENT MUTATIONS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA WITH RESISTANCE TO TYROSINE KINASE INHIBITOR TREATMENT

EHA Library, Daria Kustova, 386489

EFFECT OF VITAMIN K2 ON COVID-19 S1 PROTEIN-INDUCED CYTOTOXICITY AGAINST HUVECS AND ON THE ACTION OF ASCIMINIB IN ABELSON-TYROSINE-KINASE-INHIBITOR-RESISTANT CHRONIC MYELOGENOUS LEUKEMIA CELLS

EHA Library, Seiichi Okabe, 386490

POST HOC ANALYSIS OF PATIENT RESPONSES BY T315I MUTATION STATUS FROM THE 3-YEAR UPDATE OF THE OPTIC TRIAL: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB

EHA Library, Jorge Cortes, 386491

MULTICENTER, PROSPECTIVE AND RETROSPECTIVE OBSERVATIONAL COHORT STUDY OF PONATINIB IN PATIENTS WITH CML IN ITALY: LONG-TERM FOLLOW-UP RESULTS OF THE OITI TRIAL

EHA Library, Massimo Breccia, 386492

REAL-WORLD ANALYSIS OF MUTATION CHARACTERISTICS AND CLINICAL OUTCOMES IN 343 CHRONIC MYELOID LEUKEMIA PATIENTS WITH BCR::ABL KINASE DOMAIN MUTATIONS

EHA Library, Shiwei Hu, 386493

RAPID AND DEEP RESPONSES WITH ASCIMINIB IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS (TKIS) IN THE PHASE 3 ASCEMBL STUDY

EHA Library, Tim Hughes, 386494

1 YEAR RESULTS OF DASATINIB 70MG/DAY VERSUS 100MG/DAY IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE(CML-CP):A PROSPECTIVE RANDOMIZED CONTROLLED STUDY.

EHA Library, weiming li, 386495

RISK OF PROGRESSION IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS ELIGIBLE FOR TYROSINE KINASE INHIBITOR DISCONTINUATION: FINAL ANALYSIS OF THE TFR-PRO STUDY

EHA Library, Carlo Gambacorti-Passerini, 386496

CHRONIC MYELOID LEUKEMIA SURVEY ON UNMET NEEDS (CML SUN): BALANCING TOLERABILITY AND EFFICACY GOALS OF PATIENTS AND PHYSICIANS THROUGH SHARED TREATMENT DECISION-MAKING

EHA Library, Fabian Lang, 386497

ANALYSIS OF FACTORS INFLUENCING THE DECISION TO STOP TKI TREATMENT IN CML PATIENTS IN DEEP MOLECULAR RESPONSE

EHA Library, Lukas Semerad, 386498

EARLY CYTOGENETIC OR MOLECULAR LANDMARK RESPONSE TO PONATINIB TREATMENT PREDICTS OUTCOMES IN HEAVILY PRETREATED PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA IN PACE: 5-YEAR DATA

EHA Library, Martin Mueller, 386499

USE OF RT-QPCR VERSUS DIGITAL DROPLET PCR AND EVALUATION OF CD26+ CELLS IN LONG TFR PATIENTS WITH CHRONIC MYELOID LEUKEMIA

EHA Library, Laura De Fazio, 386500

CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND T315I MUTATION AFTER FAILURE OF PRIOR THERAPIES

EHA Library, Fadi Haddad, 386501

ASCIMINIB MANAGMENT IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH T315I MUTATION.

EHA Library, Elena Kuzmina, 386502

2ND-LINE PONATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) PATIENTS FAILING OR INTOLERANT TO 1ST-LINE 2ND GENERATION TKI THERAPY: INTERIM ANALYSIS OF THE PROSPECTIVE PONS TRIAL

EHA Library, Philipp Le Coutre, 386503

IMATINIB THERAPY IN PREVIOUSLY UNTREATED CHRONIC MYELOID LEUKAEMIA PATIENTS WHO ACHIEVE MMR AFTER 12 MONTHS THERAPY WITH DASATINIB: A STRATEGY TO AVOID LONG TERM OFF TARGET TOXICITY

EHA Library, Lucy Pemberton, 386504

UPDATED RESULTS FROM THE TRIAL ITCC-054/COG-AAML1921: BOSUTINIB IN NEWLY DIAGNOSED AND RESISTANT/INTOLERANT PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA

EHA Library, Erica Brivio, 386505

THE FACTORS OF LATE MOLECULAR RELAPSES AFTER TYROSINE KINASE INHIBITORS DISCONTINUATION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA

EHA Library, Anna Petrova, 386506

EARLY WARNING RESPONSES IN CML PATIENTS: A REAL-LIFE TURIN EXPERIENCE

EHA Library, Valentina Giai, 386507

SPOTLIGHT ON THE REAL-WORLD TREATMENT OF CML PTS IN GERMANY: A RETROSPECTIVE SURVEY IN PRIVATE ONCOLOGY PRACTICES

EHA Library, Georg-Nikolaus Franke, 386508

PONATINIB 15 MG AS CONSOLIDATION PRIOR TO TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA

EHA Library, Valentin Garcia Gutierrez, 386509

MATCHING-ADJUSTED INDIRECT COMPARISON OF ASCIMINIB VERSUS OTHER TYROSINE KINASE INHIBITORS IN THIRD-OR-LATER LINE CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA

EHA Library, Ehab Atallah, 386510

THE RESULTS OF THE RUSSIAN PROSPECTIVE STUDY OF REDUCTION AND DISCONTINUATION TREATMENT OF TKI (READIT-2020) IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH DEEP MOLECULAR RESPONSE

EHA Library, Margarita Gurianova, 386511

TRIALS IN PROGRESS: FIRST-IN-HUMAN STUDY OF ELVN-001, A SELECTIVE BCR::ABL1 TYROSINE KINASE INHIBITOR, IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA WHO FAILED PREVIOUS TYROSINE KINASE INHIBITOR THERAPIES

EHA Library, Helen Collins, 386512

A MULTICENTER RETROSPECTIVE STUDY IN CHINA: CLINICAL CHARACTERISTICS AND PROGNOSIS OF PATIENTS WITH CML-CP TREATED WITH DIFFERENT TYROSINE KINASE INHIBITORS

EHA Library, Jian Huang, 386513

LATE PHASE BCR-ABL DECLINE PREDICTS THE DURATION OF TKI (IMATINIB) FOR SUCCESSFUL TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA.

EHA Library, Chethan R, 386514

REAL-WORLD EFFICACY PROFILE OF ASCIMINIB IN AN ITALIAN, MULTI-RESISTANT CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENT POPULATION

EHA Library, Massimo Breccia, 386515

EARLY RESULTS OF A PHASE II STUDY EVALUATING THE ADDITION OF ASCIMINIB TO ERADICATE MINIMAL RESIDUAL DISEASE IN CHRONIC MYELOID LEUKEMIA

EHA Library, Aram Bidikian, 386516

ASC2ESCALATE: A US PHASE 2, OPEN-LABEL, SINGLE-ARM, DOSE-ESCALATION STUDY OF ASCIMINIB MONOTHERAPY IN 2ND-LINE (2L) TREATMENT OF PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)

EHA Library, Ehab Atallah, 386517

CLASSIFICATION OF MDS AND AML BASED SOLELY ON GENETICS OMITTING BLAST COUNTING – A WAY TO RESOLVE THE DISCREPANCIES BETWEEN CLASSIFICATIONS ACCORDING TO WHO AND ICC?

EHA Library, Claudia Haferlach, 386518

IDENTIFICATION OF CLINICALLY RELEVANT VARIANT-LEVEL SEX-BIAS IN SF3B1 K700/K666 AND IDH2 R140/R172

EHA Library, Maki Sakuma, 386519

MULTIOMIC SINGLE-CELL APPROACH REVEALED CLONAL ARCHITECTURE OF KIT MUTATIONS IN CHRONIC MYELOMONOCYTIC LEUKAEMIA PATIENTS WITH/WITHOUT SYSTEMIC MASTOCYTOSIS

EHA Library, Yu-Hung Wang, 386520

THE KEAP1-NRF2 REDOX PATHWAY IS OF CENTRAL IMPORTANCE DURING 5-AZACYTIDINE THERAPY AND THE DEVELOPMENT OF RESISTANCE VIA A SPECIFIC SET OF PROTEIN OXIDATIVE MODIFICATIONS

EHA Library, Kristýna Pimková, 386521

RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED?

EHA Library, Gregor Hoermann, 386523

SINGLE-CELL MULTIOMICS ANALYSIS OF MYELODYSPLASTIC SYNDROME PREDICTS CLINICAL RESPONSE TO TREATMENT WITH DNA DEMETHYLATION AGENT

EHA Library, Ignacio Campillo-Marcos, 386524

DYNAMICS OF CLONAL EVOLUTION IN CHRONIC MYELOMONOCYTIC LEUKEMIA WITH PROGRESSION TO SECONDARY ACUTE MYELOID LEUKEMIA: PAIRED-SAMPLE COMPARISON

EHA Library, Hsiao-Wen Kao, 386525

DISTINCT SPLICING ALTERATIONS ASSOCIATED WITH CLINICAL RESPONSE TO LUSPATERCEPT IN PATIENTS WITH LOWER‑RISK MYELODYSPLASTIC SYNDROMES FROM THE MEDALIST STUDY

EHA Library, Amit Verma, 386526

CRISPR/CAS9 GENE EDITING IN HEMATOPOIETIC STEM CELLS TO MODEL CLONAL COMPETITION IN VIVO AND IN VITRO FOR GATA2 DEFICIENCY

EHA Library, Damia Romero-Moya, 386527

MAGROLIMAB ALTERS THE TUMOR MICROENVIRONMENT TO IMPROVE BONE MARROW FUNCTIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS)

EHA Library, Lisa Johnson, 386528

THE MECHANISM OF SETD2 IN MESENCHYMAL STEM CELLS REGULATED UBA5 IN MDS ERYTHROID DIFFERENTIATION

EHA Library, Roujia Wang, 386529

SYSTEMATIC ANALYSIS OF T LYMPHOCYTES IN MYELOID NEOPLASMS

EHA Library, Ioannis Kotsianidis, 386530

APPLICATION OF NEXT GENERATION SEQUENCING (NGS) FOR MINIMAL RESIDUAL DISEASE (MRD) AND CHIMERISM MONITORING IN MYELODYSPLASTIC SYNDROME (MDS) AFTER ALLOGENIC STEM CELL TRANSPLANTATION (ASCT)

EHA Library, Irene Zamanillo, 386531

THE AIPSS-MDS MACHINE LEARNING MODEL PREDICTS OVERALL SURVIVAL AND LEUKEMIC TRANSFORMATION IN CMML: AN ANALYSIS OF THE SPANISH REGISTRY OF MDS

EHA Library, Adrian Mosquera Orgeira, 386532

ABERRANT IMMUNE MICROENVIRONMENT IN BONE MARROW OF MYELODYSPLASTIC SYNDROME PATIENTS DRIVES A SUPPRESSIVE PHENOTYPE

EHA Library, Richa Rai, 386533

AZACYTIDINE THERAPY REVERTS MDS-ASSOCIATED CHANGES IN MSC-DERIVED EXTRACELLULAR MATRIX

EHA Library, Amanpreet Bains, 386534

RESISTANCE TO HYPOMETHYLATING AGENTS (HMA) IN HIGH-RISKMYELODYSPLASTIC SYNDROME (HR-MDS): THE ROLE OF THE ADENOSINEDEAMINASE ACTING ON RNA 1 (ADAR1) ENZYME

EHA Library, Ioannis Kotsianidis, 386535

MUTATIONS IN THE COHESIN GENE STAG2 ARE ASSOCIATED WITH REDUCED INFLAMMATORY GENEEXPRESSION AND AN INCREASE IN HEMATOPOIETIC STEM CELL POPULATIONS IN MYELODYSPLASTICSYNDROME PATIENTS

EHA Library, Shubhra Ashish Bhattacharya, 386536

HIGH MUTATIONAL CONCORDANCE IN PAIRED BONE MARROW AND PERIPHERAL BLOOD SAMPLES IN PATIENTS WITH CONFIRMED OR SUSPECTED MYELODYSPLASTIC NEOPLASM

EHA Library, Natalie Wossidlo, 386537

H2AK119UB IN THE TRANSCRIPTIONAL REGULATION OF PATIENTS WITH ASXL1-MUTANT CHRONIC MYELOMONOCYTIC LEUKEMIA

EHA Library, Moritz Binder, 386538

MONOCYTES MEDIATE NK CELL FUNCTION EXHAUSTION IN MDS PATIENTS VIA CD200/CD200R PATHWAY

EHA Library, Yixuan Guo, 386539

THE PREVALENCE OF FOXP3-E2 ISOFORM IN REGULATORY T CELLS CORRELATES WITH THE DEGREE OF DYSPLASIA IN MYELODYSPLASTIC SYNDROMES

EHA Library, Stefania Leone, 386540

SOLUBLE PD-L1 PREDICT POOR OVERALL SURVIVAL AND DISEASE PROGRESSION IN PATIENTS WITH DE NOVO MYELODYSPLASTIC SYNDROME

EHA Library, Xingcheng Yang, 386541

EXPLORING CLONAL COMPETITION THROUGH 12-YEAR FOLLOW-UP OF AN MDS-RS PATIENT WITH DUAL SF3B1 MUTATIONS

EHA Library, Pedro Moura, 386542

DISSECTING THE CLINICAL HETEROGENEITY OF ISOLATED TRISOMY 8 MYELODYSPLASTIC SYNDROMES THROUGH MUTATIONAL PROFILE

EHA Library, Sofía María Toribio Castelló, 386543

TOX REGULATED CD8+ T LYMPHOCYTES EXHAUSTED IN MYELODYSPLASTIC SYNDROMES PATIENTS THROUGH ACTIVATING AKT/PI3K/MTOR PATHWAY

EHA Library, Huaquan Wang, 386544

GENE EXPRESSION ANALYSIS REVEALS UNIQUE CHARACTERISTICS OF BONE MARROW MESENCHYMAL STROMAL CELLS IN MYELODYSPLASTIC SYNDROME WITH RING SIDEROBLASTS

EHA Library, WANSHU CHEN, 386545

AG946, A PYRUVATE KINASE (PK) ACTIVATOR IMPROVES PK PROPERTIES AND RED BLOOD CELL (RBC) METABOLISM UPON EX VIVO TREATMENT OF RBCS FROM PATIENTS WITH MYELODYSPLASTIC SYNDROMES

EHA Library, Jonathan de Wilde, 386546

EPIGENOME PROFILING REVEALS ABERRANT DNA METHYLATION SIGNATURE IN GATA2 DEFICIENCY

EHA Library, Alessandra Giorgetti, 386547

RANDOMIZED PHASE 1-2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS

EHA Library, Guillermo Garcia-Manero, 386548

A BONE MARROW MICROENVIRONMENTAL CELL SIGNATURE SCORING SYSTEM INDEPENDENTLY PREDICTED SURVIVAL AND DRUG RESISTANCE IN CHRONIC MYELOMONOCYTIC LEUKAEMIA PATIENTS

EHA Library, Yu-Hung Wang, 386549

VALIDATION OF THE MOLECULAR INTERNATIONAL PROGNOSTIC SCORING SYSTEM IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES DEFINED BY INTERNATIONAL CONSENSUS CLASSIFICATION

EHA Library, Wan Hsuan Lee, 386550

CHARACTERISATION OF PHF6 MUTATIONS IN MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE

EHA Library, Aref Al-Kali, 386551

CLINICAL AND MOLECULAR ASSOCIATIONS WITH OUTCOMES IN HIGHER RISK MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS PLUS VENETOCLAX

EHA Library, Alexandre Bazinet, 386552

UPDATED SUBSTUDY RESULTS FOR IVOSIDENIB IN IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME

EHA Library, Courtney DiNardo, 386553

BATTLE OF THE GIANTS – COMPARISON OF IPSS-M AND IPSS-R IN PATIENTS WITH MISSING MOLECULAR DATA EXCEPT TP53 MUTATION STATUS FROM THE DÜSSELDORF MDS REGISTRY

EHA Library, Felicitas Schulz, 386554

HYPERCOAGULABILITY BIOMARKERS AND THROMBIN GENERATION (TG) PREDICT VENOUS THROMBOEMBOLISM (VTE) IN METASTATIC LUNG CANCER PATIENTS

EHA Library, Patricia Gomez-Rosas, 388006